Amwell Q4 net loss at USD 25.2 million, total revenue at USD 55.3 million

Reuters
02/13
Amwell Q4 net loss at USD 25.2 million, total revenue at USD 55.3 million

Amwell reported its financial results for the fourth quarter (Q4) and full year (FY) ended December 31, 2025. For Q4 2025, Amwell recorded total revenue of USD 55.3 million, exceeding previously provided financial guidance. Subscription revenue reached USD 28.8 million, while Amwell Medical Group $(AMG)$ visit revenue was USD 23.7 million. Gross margin for the quarter was 51%. The company reported a net loss of USD 25.2 million and adjusted EBITDA of negative USD 10.3 million. Total visits for the quarter were 1.0 million. For the full year 2025, Amwell recorded total revenue of USD 249.3 million, including subscription revenue of USD 132.4 million. In 2025, Amwell focused on its Technology Enabled Care platform, aiming to address unmet needs across Government, Payer, and Health System clients. The company highlighted its ability to support both proprietary and third-party AI-powered clinical programs, alongside achieving strong market validation through contract renewals and new client acquisitions. Amwell indicated that it had transformed its cost base and elevated revenue quality during the period. Looking ahead, Amwell provided guidance for the first quarter (Q1) of 2026, projecting revenue in the range of USD 48 million to USD 53 million and adjusted EBITDA in the range of negative USD 7 million to negative USD 5 million. The company also communicated its objective to achieve positive cash flow from operations in the fourth quarter of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. American Well Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-048737), on February 12, 2026, and is solely responsible for the information contained therein.

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10